Safety scare with AstraZeneca’s diabetes drug could shake up the DPP-4 field

Damian Garde

The FDA raised some alarming concerns tied to AstraZeneca's Onglyza ahead of a committee meeting to discuss the of so-called DPP-4 inhibitors, sounding a worrying note for a blockbuster class of drugs.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS